Hydroxyurea (hydroxycarbamide)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-HYDROXYUREA |
|---|---|
| Type | Drug |
| Aliases | HCHUHydreaHydroxycarbamideHydroxyureaLitalirГідроксикарбамід |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | DIS-ET DIS-PV |
| Sources | SRC-ESMO-MPN-2015 SRC-NCCN-MPN-2025 |
Drug Facts
| Class | Antimetabolite (ribonucleotide reductase inhibitor) |
|---|---|
| Mechanism | Inhibits ribonucleotide reductase → blocks DNA synthesis. Preferentially reduces blood-cell production. Workhorse cytoreduction for high-risk PV/ET and CML pre-TKI era; still used for sickle-cell disease and palliative CMML/MPN-AML cytoreduction. |
| Ukraine registered | True |
| NSZU reimbursed | True |
| Ukraine last verified | 2026-04-27 |
Warnings
- Severe myelosuppression
- Secondary malignancies (leukemia, skin cancer with chronic use)
Notes
1L cytoreduction for high-risk PV (age >60 OR prior thrombosis) and high-risk ET (same criteria). Goals: PV — Hct <45%, plt <400K; ET — plt <400K. Pegylated interferon-α (ropeginterferon for PV) is emerging alternative with potential disease-modifying activity but access-limited. Anagrelide is 2L for ET (PT-1 trial — non-inferior on thrombosis but more bleeding/cardiac side effects).
Used By
Regimens
REG-HU-PV-ET- Hydroxyurea (PV / ET high-risk 1L cytoreduction) + baseline phlebotomy/ASA